Empagliflozin in acute myocardial infarction reduces no-reflow and preserves cardiac function by preventing endothelial damage
Myocardial infarct size (IS) and now reflow are major determinants of prognosis and currently there are no effective treatments. We investigated the effects of empagliflozin on cardiac cell populations affected by myocardial ischemia reperfusion injury (IRI), and its cardioprotective potential in terms of IS and no-reflow. Overall design: 38 total RNA samples were used for library construction. RNA concentration was determined using a Qubit-4 Fluorometer (Invitrogen) and the Qubit RNA HS Assay Kit (Invitrogen).RNA quality was determined on an Agilent 2100 Bioanalyzer(Agilent) using the Agilent RNA 6000 Nano Kit (Agilent) and protocol. For library preparation, the QuantSeq 3' mRNA-Seq Library Prep Kit for Illumina (FWD) (Lexogen) was used according to manufacturer's instructions. Briefly, up to 500?ng of RNA from each sample were used for first strand synthesis, followed by RNA template removal. Second strand synthesis was initiated by random primers containing compatible linker sequences at its 5' end. In-line barcodes were introduced during second strand synthesis followed by magnetic bead-based purification; the resulting libraries were amplified for up to 15 cycles and re-purified. Quality and quantity of libraries were assessed on an Agilent 2100 Bioanalyzer using the High Sensitivity DNA Kit reagents and protocol (Agilent). The quantified libraries were pooled at a final concentration of 2 nM and sequenced on a  NextSeq 550 System (Illumina), according to manufacturer's instructions.